Universal cancer peptides derived from telomerase

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10695409
APP PUB NO 20170360914A1
SERIAL NO

15609638

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to a peptide of 15 to 20 amino acids deriving from TERT protein, which peptide is capable of (i) binding to HLA class II and (ii) stimulating a CD4 Th response. These universal cancer peptides are especially useful in anti-tumor immunotherapy and immunomonitoring.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UNIVERSITE DE FRANCHE-COMTE25000 BESANÇON
CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE BESANCON2 PLACE SAINT-JACQUES BESANÇON CEDEX 25030
INVECTYS75015 PARIS

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Adotevi, Olivier Besancon, FR 7 45
Dosset, Magalie Besancon, FR 2 6
Langlade, Demoyen Pierre Neuilly sur Seine, FR 27 34

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 30, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 30, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00